Search Results - "Martínez Jáñez, Noelia"

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments by Cortés, Alfonso, Casado, José L., Longo, Federico, Serrano, Juan J., Saavedra, Cristina, Velasco, Héctor, Martin, Adrián, Chamorro, Jesús, Rosero, Diana, Fernández, María, Gion, María, Martínez Jáñez, Noelia, Soria Rivas, Ainara, Alonso Gordoa, Teresa, Martínez Delfrade, Íñigo, Lage, Yolanda, López Miranda, Elena, Olmedo, María E., Reguera Puertas, Pablo, Gajate, Pablo, Molina Cerrillo, Javier, Guerra Alia, Eva, Fuentes Mateos, Raquel, Romero, Beatriz, Rodríguez-Domínguez, Mario J., Vallejo, Alejandro, Carrato, Alfredo

“…Patients with cancer (PC) are at high risk of acquiring COVID-19 and can develop more serious complications. Deeper understanding of vaccines immunogenicity in…”
Get full text

Myocarditis and carotidynia caused by Granulocyte-Colony stimulating factor administration by Corral de la Fuente, Elena, Barquín Garcia, Arantza, Saavedra Serrano, Cristina, Serrano Domingo, Juan José, Martín Huertas, Roberto, Fernández Abad, María, Martínez Jáñez, Noelia

“…A 59 year-old woman was treated with adjuvant chemotherapy for triple negative breast cancer (TNBC) stage IB. She received pegfilgrastrim as secondary…”
Get full text

Prolonged Responses With Trastuzumab Emtasine Treatment of Human Epidermal Growth Factor Receptor 2-positive Metastatic Breast Cancer Refractory to Trastuzumab and Pertuzumab: Systematic Review of Evidence by Martin Huertas, Roberto, Fernández Abad, María, Corral de la Fuente, Elena, Serrano Domingo, Juan José, Martínez Jáñez, Noelia

“…Amplification of human epidermal growth factor receptor 2 (HER2) occurs in around 25% of breast cancers and has been associated with aggressive disease. Here,…”
Get full text

Sapanisertib plus Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive/HER2-Negative Advanced Breast Cancer after Progression on Aromatase Inhibitor by García-Sáenz, José Á, Martínez-Jáñez, Noelia, Cubedo, Ricardo, Jerez, Yolanda, Lahuerta, Ainhara, González-Santiago, Santiago, Ferrer, Nieves, Ramos, Manuel, Alonso-Romero, Jose L, Antón, Antonio, Carrasco, Eva, Chen, Jingjing, Neuwirth, Rachel, Galinsky, Kevin, Vincent, Sylvie, Leonard, E Jane, Slamon, Dennis

“…This phase II study investigated daily or weekly sapanisertib (a selective dual inhibitor of mTOR complexes 1 and 2) in combination with fulvestrant…”
Get full text

XENERA-1: a randomised double-blind Phase II trial of xentuzumab in combination with everolimus and exemestane versus everolimus and exemestane in patients with hormone receptor-positive/HER2-negative metastatic breast cancer and non-visceral disease by Schmid, Peter, Cortes, Javier, Joaquim, Ana, Jañez, Noelia Martínez, Morales, Serafín, Díaz-Redondo, Tamara, Blau, Sibel, Neven, Patrick, Lemieux, Julie, García-Sáenz, José Ángel, Hart, Lowell, Biyukov, Tsvetan, Baktash, Navid, Massey, Dan, Burris, 3rd, Howard A, Rugo, Hope S

“…Xentuzumab is a humanised monoclonal antibody that binds to IGF-1 and IGF-2, neutralising their proliferative activity and restoring inhibition of AKT by…”
Get full text

Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study by Villarroel, Paula González, Padró, Josep Gumà, Marquina, Gloria, Jáñez, Noelia Martínez, González, Emilio Esteban, Antón, Antonio, Sánchez, Miguel Berzosa, Cáceres, Alberto Rodrigo, López-López, Rafael, Cornejo, Roberto Escala, García, Pablo Borrega, Fabregat, Raquel Marse, Fernández, Beatriz Castelo, Bermudo, Cristina López, Camps, Carlos

“…To evaluate the quality of life (QoL) in patients with breakthrough cancer pain (BTcP) in Spanish medical oncology departments. In a prospective,…”
Get full text

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature by Albarrán, Víctor, Chamorro, Jesús, Pozas, Javier, San Román, María, Rosero, Diana Isabel, Saavedra, Cristina, Gion, María, Cortés, Alfonso, Escalera, Elena, Guerra, Eva, López Miranda, Elena, Fernández Abad, María, Martínez Jañez, Noelia

“…PARP inhibitors are progressively becoming a part of our therapeutic arsenal against BRCA-defective tumors, because of their capacity to induce synthetic…”
Get full text

Safety and efficacy of ribociclib plus letrozole in patients with HR+, HER2– advanced breast cancer: Results from the Spanish sub-population of the phase 3b CompLEEment-1 trial by Salvador Bofill, Javier, Moreno Anton, Fernando, Rodriguez Sanchez, Cesar Augusto, Galve Calvo, Elena, Hernando Melia, Cristina, Ciruelos Gil, Eva Maria, Vidal, Maria, Jiménez-Rodriguez, Begoña, De la Cruz Merino, Luis, Martínez Jañez, Noelia, Villanueva Vazquez, Rafael, de Toro Salas, Ruben, Anton Torres, Antonio, Alvarez Lopez, Isabel Manuela, Gavila Gregori, Joaquin, Quiroga Garcia, Vanesa, Vicente Rubio, Elena, De la Haba-Rodriguez, Juan, Gonzalez-Santiago, Santiago, Diaz Fernandez, Nieves, Barnadas Molins, Agusti, Cantos Sanchez de Ibargüen, Blanca, Delgado Mingorance, Juan Ignacio, Bellet Ezquerra, Meritxell, de Casa, Sonia, Gimeno, Asuncion, Martin, Miguel

“…Breast cancer is the most common malignancy and the second leading cause of cancer-related mortality in Spanish women. Ribociclib in combination with endocrine…”
Get full text

Quality of life with palbociclib plus fulvestrant versus placebo plus fulvestrant in postmenopausal women with endocrine-sensitive hormone receptor-positive and HER2-negative advanced breast cancer: patient-reported outcomes from the FLIPPER trial by Tibau, Ariadna, Martínez, M. Teresa, Ramos, Manuel, De La Cruz-Merino, Luis, Santaballa, Ana, O’Connor, Miriam, Martínez-Jañez, Noelia, Moreno, Fernando, Fernández, Isaura, Virizuela, Juan Antonio, Alarcón, Jesús, de La Haba-Rodríguez, Juan, Sánchez-Rovira, Pedro, Albacar, Cinta Rosa, Bueno Muiño, Coralia, Kelly, Catherine, Casas, Maribel, Bezares, Susana, Rosell, Libertad, Albanell, Joan

“…Background: In the FLIPPER trial, palbociclib/fulvestrant significantly improved progression-free survival (PFS) compared with placebo/fulvestrant in…”
Get full text

Pleomorphic lobular carcinoma of the breast with osteoclast-like giant cells: a case report and review of the literature by Peña-Jaimes, Lourdes, González-García, Irene, Reguero-Callejas, María Eugenia, Pinilla-Pagnon, Ignacio, Pérez-Mies, Belén, Albarrán-Artahona, Víctor, Martínez-Jañez, Noelia, Rosa-Rosa, Juan Manuel, Palacios, José

“…Breast carcinoma with osteoclast-like giant cells (OGCs) is infrequent, being most reported cased described as ductal invasive carcinomas. Invasive pleomorphic…”
Get full text

TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer by Bardia, Aditya, Jhaveri, Komal, Kalinsky, Kevin, Pernas, Sonia, Tsurutani, Junji, Xu, Binghe, Hamilton, Erika, Im, Seock-Ah, Nowecki, Zbigniew, Sohn, Joohyuk, Laurentiis, Michelino De, Jañez, Noelia Martínez, Adamo, Barbara, Lee, Keun Seok, Jung, Kyung Hae, Rubovszky, Gábor, Tseng, Ling-Ming, Lu, Yen-Shen, Yuan, Yuan, Maxwell, Micah J, Haddad, Vincent, Khan, Sabrina S, Rugo, Hope S, Pistilli, Barbara

“…Improving the prognosis for patients with metastatic HR+/HER2- breast cancer remains an unmet need. Patients with tumors that have progressed on endocrine…”
Get more information

A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer by Ciruelos, Eva, Apellániz‐Ruiz, María, Cantos, Blanca, Martinez‐Jáñez, Noelia, Bueno‐Muiño, Coralia, Echarri, Maria‐Jose, Enrech, Santos, Guerra, Juan‐Antonio, Manso, Luis, Pascual, Tomas, Dominguez, Cristina, Gonzalo, Juan‐Francisco, Sanz, Juan‐Luis, Rodriguez‐Antona, Cristina, Sepúlveda, Juan‐Manuel

“…Background This study aimed to characterize the neurotoxicity of three different regimens of nab‐paclitaxel compared with a standard regimen of solvent‐based…”
Get full text

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study by Freyer, Gilles, Martinez-Jañez, Noelia, Kukielka-Budny, Bożena, Ulanska, Malgorzata, Bourgeois, Hugues, Muñoz, Montserrat, Morales, Serafin, Calero, Juan Bayo, Cortesi, Laura, Pintér, Tamás, Palácová, Markéta, Cherciu, Nelli, Petru, Edgar, Ettl, Johannes, de Almeida, Cécilia, Villanova, Gustavo, Raymond, Romain, Minh, Christine Ta Thanh, Rodrigues, Ana, Cazzaniga, Marina E.

“…Single-agent oral vinorelbine is a standard of care for hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast…”
Get full text

A phase Ib study evaluating the recommended phase II dose, safety, tolerability, and efficacy of mivavotinib in combination with nivolumab in advanced solid tumors by Juric, Dejan, Barve, Minal, Vaishampayan, Ulka, Roda, Desamparados, Calvo, Aitana, Jañez, Noelia Martinez, Trigo, Jose, Greystoke, Alastair, Harvey, R. Donald, Olszanski, Anthony J., Opyrchal, Mateusz, Spira, Alexander, Thistlethwaite, Fiona, Jiménez, Begoña, Sappal, Jessica Huck, Kannan, Karuppiah, Riley, Jason, Li, Cheryl, Li, Cong, Gregory, Richard C., Miao, Harry, Wang, Shining

“…Mivavotinib (TAK‐659/CB‐659), a dual SYK/FLT3 inhibitor, reduced immunosuppressive immune cell populations and suppressed tumor growth in combination with…”
Get full text

Prospective evaluation of the conversion rate in the receptor status between primary breast cancer and metastasis: results from the GEICAM 2009-03 ConvertHER study by de Dueñas, Eduardo Martínez, Hernández, Ana Lluch, Zotano, Ángel Guerrero, Carrión, Ramón María Pérez, López-Muñiz, José Ignacio Chacón, Novoa, Silvia Antolín, Rodríguez, Ángela López, Fidalgo, José Alejandro Pérez, Lozano, Jaime Ferrer, Gasión, Octavio Burgués, Carrascal, Eva Carrasco, Capilla, Andrés Hernando, López-Barajas, Isabel Blancas, Mateu, Montserrat Muñoz, de Ceballos Reyna, María Helena López, Ferrando, Amparo Oltra, Jañez, Noelia Martínez, Ballerini, Vicente Carañana, Torres, Antonio Antón, Catalán, Gustavo, Sáenz, José Ángel García, Menjón, Salomón, González-Angulo, Ana María

“…The objective of this study was to determine the conversion rate of human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER) and progesterone…”
Get full text

Long-Term Cardiac Safety and Survival Outcomes of Neoadjuvant Pegylated Liposomal Doxorubicin in Elderly Patients or Prone to Cardiotoxicity and Triple Negative Breast Cancer. Final Results of the Multicentre Phase II CAPRICE Study by Gil-Gil, Miguel J., Bellet, Meritxell, Bergamino, Milana, Morales, Serafín, Barnadas, Agustí, Manso, Luís, Saura, Cristina, Fernández-Ortega, Adela, Garcia-Martinez, Elena, Martinez-Jañez, Noelia, Melé, Mireia, Villagrasa, Patricia, Celiz, Pamela, Perez Martin, X., Ciruelos, Eva, Pernas, Sonia

“…BACKGROUNDThe CAPRICE trial was designed to specifically evaluate neoadjuvant pegylated liposomal doxorubicin (PLD) in elderly patients or in those with other…”
Get full text

Anthracyclines-induced cardiotoxicity in patients with early breast cancer carrying germline BRCA1/2 mutation: the BRCAN study by Cortés-Salgado, Alfonso, Serrano, Juan José, Cordero Pereda, David, Menacho, Miriam, Del Rey, José Manuel, del Campo-Albendea, Laura, Saavedra, Cristina, Chamorro, Jesús, Rosero, Diana, Sotoca, Pilar, Guillén-Ponce, Carmen, Guerra, Eva, Fernández-Abad, María, López-Miranda, Elena, Martínez-Jáñez, Noelia, Gion, María, Salazar, María Teresa, Agudo-Quílez, Pilar, Garrido, Pilar, Alonso Salinas, Gonzalo Luis

“…BRCA1/2 genes play a critical role in genome stability and DNA repair. In animal models, loss of cardiomyocyte-specific BRCA1/2 is associated with DNA damage,…”
Get full text

Abstract PD1-01: Open-label, randomized, phase 2 study of sapanisertib (TAK-228/MLN0128) in combination with fulvestrant in postmenopausal women with estrogen receptor-positive (ER+)/human epidermal growth factor receptor-2-negative (HER2-) advanced or metastatic breast cancer (MBC) that previously progressed during or after aromatase inhibitor therapy (NCT02756364) by García-Saenz, José Á, Jáñez, Noelia Martínez, Martin, Miguel, Martínez, Ainhara Lahuerta, González-Santiago, Santiago, Ferrer, Nieves, Vázquez, Manuel Ramos, Romero, José Luis Alonso, Antón, Antonio, Carrasco, Eva, Chen, Jingjing, Neuwirth, Rachel, Leonard, E Jane, Slamon, Dennis

“…Background: Sapanisertib (S) is an investigational, oral, and highly selective adenosine triphosphate (ATP)-competitive inhibitor of target of rapamycin…”
Get full text

Male breast cancer - An orphan entity by Chamorro Pérez, Jesús, Moreno Doval, Jaime, González Merino, Carlos, Martínez Jáñez, Noelia

Get full text

First Line of palliative treatment for breast cancer HER2 by Pérez de Aguado Rodríguez, Patricia, Alía Navarro, Víctor, Martínez Jáñez, Noelia

Get full text